Relevant bibliographies by topics / 003.26:621.39 (043.3)

Contents

  1. Journal articles
  2. Conference papers

Academic literature on the topic '003.26:621.39 (043.3)'

Author: Grafiati
Published: 30 May 2022
Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic '003.26:621.39 (043.3).'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "003.26:621.39 (043.3)"

1

Aguirre, Luis E., Jan Philipp Bewersdorf, Yiwen Liu, et al. "Comparative Analysis of Outcomes with HMA Plus Venetoclax Vs Intensive Chemotherapy in AML Patients Harboring Very-High Risk Cytogenetics." Blood 144, Supplement 1 (2024): 4267. https://doi.org/10.1182/blood-2024-202744.

Full text
Abstract:
Background: Dismal survival outcomes are characteristic of pts with AML harboring very-high risk cytogenetics (vHRC), which can be attributed to aggressive disease biology and low and poorly durable response rates to conventional cytotoxic chemotherapy. Allogeneic hematopoietic stem cell transplant (alloSCT) is the preferred treatment strategy after major disease reduction with initial chemotherapy. However, it is unclear whether pts with AML-vHRC should be treated with intensive chemotherapy (IC) or hypomethylating agents plus venetoclax (HMA+ven) to achieve such responses. In this large mult
APA, Harvard, Vancouver, ISO, and other styles
2

Calvo Garcia, A., N. García Castañeda, C. Valero, et al. "AB0334 COST-EFECTIVENESS OF JAK INHIBITORS IN RHEUMATOID ARTHRITIS IN THE REAL WORL PRACTICE." Annals of the Rheumatic Diseases 79, Suppl 1 (2020): 1465.1–1466. http://dx.doi.org/10.1136/annrheumdis-2020-eular.4982.

Full text
Abstract:
Background:The Janus Kinase (JAK) inhibitors Baricitinib (BAR) and Tofacitinib (TOF), both in monotherapy or in combination with methotrexate, are indicated for moderate to severe active rheumatoid arthritis (RA) with inadequate response to conventional synthetic disease modifying anti-rheumatic drugs (csDMARD). Data about cost-effectiveness in a real-world setting are still scarce.Objectives:To assess the cost-effectiveness (C-E) of BAR and TOF in patients with RA in usual clinical practice.Methods:Retrospective observational study of adult RA patients who started BAR and TOF between Septembe
APA, Harvard, Vancouver, ISO, and other styles
3

Arndt, C. A., D. S. Hawkins, J. A. Stoner, et al. "Randomized phase III trial comparing vincristine, actinomycin, cyclophosphamide (VAC) with VAC/V topotecan/cyclophosphamide (TC) for intermediate risk rhabdomyosarcoma (IRRMS). D9803, COG study." Journal of Clinical Oncology 25, no. 18_suppl (2007): 9509. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.9509.

Full text
Abstract:
9509 Background: IRRMS was defined as nonmetastatic alveolar (A) RMS or undifferentiated sarcoma (UDS); stage (stg) 2 and 3, group (gr) III embryonal (E) RMS; stg 4 ERMS <10y. IRRMS had a 5 yr failure free survival (FFS) of 64% on IRS IV. Since T alone and with C has significant activity in RMS, we tested whether alternating VAC/VTC improved FFS for IRRMS compared with VAC alone. Methods: Patients (pts) < 50 y with IRRMS with adequate organ function were randomized to 39 wks of VAC (V=1.5 mg/m2, A=0.045 mg/kg, C=2.2 g/m2 q 3 wk) vs VAC alternating with VTC (T=0.75 mg/m2/d ×5, C=250 mg/m2
APA, Harvard, Vancouver, ISO, and other styles
4

Issa, Ghayas C., Hagop M. Kantarjian, C. Cameron Yin, et al. "Prognostic Implications of Pre-Treatment Hypodiploidy and Complex Cytogenetics in Adult Patients with Acute Lymphocytic Leukemia (ALL) Treated with Hyper-CVAD." Blood 126, no. 23 (2015): 4874. http://dx.doi.org/10.1182/blood.v126.23.4874.4874.

Full text
Abstract:
Abstract Background Pretreatment cytogenetic analysis is frequently used to predict response and outcome in hematologic malignancies. Hypodiploidy is associated with a poor prognosis in childhood ALL. Similarly, complex cytogenetics is a known adverse prognostic factor in myeloid malignancies. The impact of hypodiploidy and complex cytogenetics has not been extensively assessed in adult patients with ALL. To address this issue, we have conducted a retrospective analysis of all adult patients with ALL treated with frontline Hyper-CVAD based regimens at our institution. Methods We reviewed 332 a
APA, Harvard, Vancouver, ISO, and other styles
5

Angeles-Han, S., A. Cassedy, T. Hennard, et al. "POS1303 METHOTREXATE RESPONSE IN PEDIATRIC NON-INFECTIOUS UVEITIS." Annals of the Rheumatic Diseases 81, Suppl 1 (2022): 989–90. http://dx.doi.org/10.1136/annrheumdis-2022-eular.1473.

Full text
Abstract:
BackgroundChildren with chronic non-infectious uveitis (NIU) are at risk for sight-threatening complications. Methotrexate (MTX) is the preferred first-line systemic treatment. Initial therapeutic response takes 3-6 months to achieve NIU control, leading to prolonged glucocorticoid use. Moreover, at least 50-70% of children fail to fully respond and may accrue ocular damage while awaiting MTX response.ObjectivesTo identify features of children with NIU that are associated with MTX failure.MethodsWe included children who started MTX monotherapy for NIU. We collected demographics, NIU features (
APA, Harvard, Vancouver, ISO, and other styles
6

Enright, Thomas L., Jacob B. Leary, Dimitra R. Bakaloudi, et al. "Abstract 3402: Number of variants of unknown significance (VUS) by next generation sequencing (NGS) and response to systemic therapies in advanced urothelial carcinoma (aUC)." Cancer Research 85, no. 8_Supplement_1 (2025): 3402. https://doi.org/10.1158/1538-7445.am2025-3402.

Full text
Abstract:
Abstract Background: NGS is routinely used in aUC to identify clinically actionable alterations. NGS assays tier variants by the likelihood of clinical significance, reporting both pathogenic variants and VUS. The number of VUS may serve as a rough estimate for neoantigen load, e.g. tumor mutational burden (TMB). We hypothesized that the number of VUS may represent an easy-to-use biomarker associated with response and overall survival (OS) with certain therapies e.g. immune checkpoint inhibitors (ICI). Methods: We conducted a retrospective study from patients (pts) from a single academic cente
APA, Harvard, Vancouver, ISO, and other styles
7

Tagawa, Scott T., Arjun V. Balar, Daniel P. Petrylak, et al. "Updated outcomes in TROPHY-U-01 cohort 1, a phase 2 study of sacituzumab govitecan (SG) in patients (pts) with metastatic urothelial cancer (mUC) that progressed after platinum (PT)-based chemotherapy and a checkpoint inhibitor (CPI)." Journal of Clinical Oncology 41, no. 6_suppl (2023): 526. http://dx.doi.org/10.1200/jco.2023.41.6_suppl.526.

Full text
Abstract:
526 Background: SG is an antibody-drug conjugate composed of an anti-Trop-2 antibody coupled to SN-38, a topoisomerase-I inhibitor, via a proprietary hydrolyzable linker. SG received accelerated FDA approval in April 2021 in pts with mUC who previously received PT-based therapy and a CPI based on the primary analysis of the pivotal TROPHY-U-01 Cohort 1 study. With 9.1 mo median (med) follow-up, SG monotherapy demonstrated a 27% objective response rate (ORR) and med overall survival (OS) of 10.9 mo in 113 pts with locally advanced or mUC progressing after receiving at least a PT-based therapy a
APA, Harvard, Vancouver, ISO, and other styles
8

Вигівська, Л. М., І. В. Майданник, О. О. Чорна, Н. М. Гичка, В. М. Комар та К. В. Коливанова. "ВПЛИВ ЗАПРОПОНОВАНОГО ЛІКУВАЛЬНО-ПРОФІЛАКТИЧНОГО КОМПЛЕКСУ НА СИСТЕМУ ГЕМОСТАЗУ, ЕНДОТЕЛІАЛЬНОГО ТА ІМУННОГО СТАТУСУ У ВАГІТНИХ ПІСЛЯ ДОПОМІЖНИХ РЕПРОДУКТИВНИХ ТЕХНОЛОГІЙ". Актуальні питання педіатрії, акушерства та гінекології, № 2 (22 січня 2025): 32–37. https://doi.org/10.11603/24116-4944.2024.2.14987.

Full text
Abstract:
Мета дослідження – визначити стан системи гемостазу, ендотеліальних факторів у жінок після застосування допоміжних репродуктивних технологій (ДРТ) на тлі запропонованого лікувально-профілактичного комплексу. Матеріали та методи. Проведено проспективне обстеження 299 вагітних, яких відповідно до типу непліддя та менеджменту поділено на: І група – 94 жінок із трубно-перитонеальним фактором непліддя; ІІ група – 87 жінок з ендокринним фактором непліддя; ІІІ група – 68 жінок із чоловічим фактором непліддя. Контрольну групу сформовано з 50 вагітних зі спонтанним настанням та фізіологічним перебігом
APA, Harvard, Vancouver, ISO, and other styles
9

Tesfaye, Solomon, Gordon Sloan, Jennifer Petrie, et al. "Optimal pharmacotherapy pathway in adults with diabetic peripheral neuropathic pain: the OPTION-DM RCT." Health Technology Assessment 26, no. 39 (2022): 1–100. http://dx.doi.org/10.3310/rxuo6757.

Full text
Abstract:
Background The mainstay of treatment for diabetic peripheral neuropathic pain is pharmacotherapy, but the current National Institute for Health and Care Excellence guideline is not based on robust evidence, as the treatments and their combinations have not been directly compared. Objectives To determine the most clinically beneficial, cost-effective and tolerated treatment pathway for diabetic peripheral neuropathic pain. Design A randomised crossover trial with health economic analysis. Setting Twenty-one secondary care centres in the UK. Participants Adults with diabetic peripheral neuropath
APA, Harvard, Vancouver, ISO, and other styles
10

Christen, Deborah, Johannes Lübke, Anne Kaiser, et al. "Allogeneic Hematopoietic Stem Cell Transplantation in Advanced Systemic Mastocytosis." Blood 142, Supplement 1 (2023): 3605. http://dx.doi.org/10.1182/blood-2023-178304.

Full text
Abstract:
Purpose Advanced systemic mastocytosis (AdvSM) is driven by the KIT D816V mutation in >90% of patients (pts.). Depending on subtype, median survival is between 1.5 and 4 years. Despite recent advances on responses and survival due to the availability of effective KIT inhibitors, allogeneic hematopoietic stem cell transplantation (alloHSCT) remains the only curative treatment option. Data on optimal timing, conditioning regimens, and pre- as well as post-alloHSCT treatments for maintenance or relapse are however scarce. Current recommendations mainly refer to a retrospective analysis pub
APA, Harvard, Vancouver, ISO, and other styles
More sources

Conference papers on the topic "003.26:621.39 (043.3)"

1

Suhas, K. R. "Audit on the role and efficacy of PET/CT in recurrent ovarian cancer settings in a tertiary care centre in India." In 16th Annual International Conference RGCON. Thieme Medical and Scientific Publishers Private Ltd., 2016. http://dx.doi.org/10.1055/s-0039-1685301.

Full text
Abstract:
Ovarian cancers tend to recur in 15-70% cases. CA-125 - is a tumor marker used for monitoring therapeutic response, and in surveillance, for recurrent disease. However, it has a limited role as a persistent high level can signify either recurrence or persistence of residual tumor. Metastases from ovarian cancer primarily involve the peritoneum rather than parenchymal sites; thus, the presence of small-volume recurrence or metastatic deposits on the visceral surfaces poses a challenge for interpretation of CT and MR images. PET/CT utilizes its property of higher accumulation in malignant cells
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic '003.26:621.39 (043.3)' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography